Cerebrolysin Peptide

Not a molecule. A processed extract of pig brain tissue, in clinical use for decades.

Cerebrolysin is not a peptide but a preparation derived from purified porcine brain protein, which mass spectrometry has characterised as 14,635 distinct peptides originating from 1,643 different porcine proteins. A 2023 Cochrane systematic review pooling seven randomised controlled trials in 1,773 acute ischaemic stroke patients reported more serious adverse events in the treated group than in placebo.

Let's do the composition first, because most pages never get to it.

Cerebrolysin isn't a peptide in the singular. It's an enzymatic digest of pig brain proteins, a soup of fragments, standardised by the recipe rather than by any one ingredient.

Think of a mixtape with 14,635 songs on it and no track list. That's the vial. It's been in clinical use across Russia, parts of Europe and Asia for decades, mostly around stroke and neurological conditions, which gives it something almost nothing else here has: a large human record.

And a large human record means somebody eventually audits it properly.

Somebody did. In 2023. It's the most important document about this product and it's three paragraphs down.

You cannot write a receptor story for a mixture, and this is a mixture.

The proposed story is that small brain-derived peptide fragments mimic the brain's own growth and maintenance signals.

As a hypothesis it isn't crazy. Brains do run on peptide signals. Yours is running on a few right now.

Which fragment does what, at what concentration, varying how much from batch to batch: those questions don't have published answers, because the product's defined by its process. You can't write a receptor story for a mixtape.

Here's the honest part, and for once it isn't about missing data.

The data exists. It's the audit of it that hurts, and that's the next section's job.

The Cochrane review is the file. Read this section before any other page about it.

In 2023 Cochrane, the closest thing evidence-based medicine has to a supreme court, reviewed the trials. Seven randomised trials, 1,773 people.

The findings, plainly: no reduction in deaths, and a relative risk of 2.39 for serious adverse events. More than double.

Decades of clinical use generated enough trials to review, and the review found the benefit missing and a safety signal present. Both halves of that sentence matter, and we'd rather you read both.

It's still used in clinics across Eastern Europe and Asia regardless, which says more about regulatory inertia than about the data.

We'll sell you the vial, and we'll also hand you the Cochrane number, because a store that only shows you one of those two things isn't a store you should trust.

This one is not a defined peptide. It is a porcine brain-derived mixture. Any purity number on a biological extract answers a narrower question than the same number on a defined molecule, and we would rather say that plainly than let a figure imply more than it can.

Read the Cochrane review. Seven randomised trials, 1,773 patients, no mortality benefit and a relative risk of 2.39 for non-fatal serious adverse events. If you are evaluating this compound, that is the document.

Same day out of British Columbia. Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.

Then into the fridge. Keep it cold and keep it dark. Once it lands, fridge. That is the whole ask.